153 Participants Needed

Articulating Spacers for Knee Infections

MJ
Overseen ByMelissa J Shauver, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Northwestern University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores two methods for treating infections in artificial knee joints. It compares a one-stage revision, where a new knee with antibiotic cement is placed, to a two-stage revision, which uses an antibiotic-releasing spacer (such as an all-cement articulating spacer or a real-component articulating spacer) before replacing the knee later. The researchers aim to determine which method patients prefer and which provides better long-term function. Individuals with long-term infections in knee replacements might find this trial suitable. As an unphased trial, it offers an opportunity to contribute to research that could enhance treatment options for future patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that these articulating spacers are safe for knee infections?

Research has shown that both all-cement and real-component spacers used in treating knee infections are generally well-tolerated. These spacers release antibiotics directly into the knee, helping to control the infection.

Studies have found that all-cement spacers manage infections as effectively as other types. Although they may not last as long as a regular artificial joint, they are safe for temporary use.

Real-component spacers, made from metal or plastic, also effectively control infections. They remain in place until the infection clears or if treatment doesn't work.

Both types of spacers use high-dose antibiotic cement, proven safe and effective for treating knee infections. It is important to note that using these spacers may require another surgery later to replace the temporary spacer with a permanent joint. Overall, these treatments have a strong safety record and are a standard option for knee infections.12345

Why are researchers excited about this trial?

Researchers are excited about the articulating spacers for knee infections because they offer innovative approaches for managing complex joint infections. Unlike traditional static spacers, the all-cement articulating spacer is made using molds and high-dose antibiotic cement, which allows for more personalized fitting and targeted infection treatment with antibiotics like vancomycin and tobramycin. Meanwhile, the durable, real-component articulating spacer uses metal or ceramicized metal with a plastic bearing surface, potentially providing a more durable, long-term solution without the need for immediate revision. Both spacers aim to reduce infection and improve joint functionality, offering new hope for patients with serious knee infections.

What evidence suggests that this trial's treatments could be effective for knee infections?

This trial compares the effectiveness of two types of articulating spacers for treating infections in artificial knees. Participants in one arm will receive an all-cement articulating spacer, made using a mold to form the joint parts. Another arm will involve a durable, real-component articulating spacer, which includes metal or ceramic parts that may function more like a real knee. Research has shown that both types of spacers release antibiotics directly into the knee to combat infections, and using a two-step process with antibiotic spacers successfully controls infections in over 80% of cases. Previous comparisons showed no significant difference in failure rates between these two types of spacers. Both options aim to clear infections and help patients regain knee function, although the choice may depend on personal preferences and other factors.12467

Who Is on the Research Team?

AI

Adam I Edelstein, MD

Principal Investigator

Assistant Professor of Orthopaedic Surgery

Are You a Good Fit for This Trial?

This trial is for patients with a chronic infection in their artificial knee joint after initial replacement surgery, who are planning to have the infected joint replaced with an antibiotic spacer. They must meet specific infection criteria and be able to consent. Those with allergies to study materials, soft tissue or bone issues at the site can't participate.

Inclusion Criteria

PJI defined according to Musculoskeletal Infection Society (MSIS) 2018 Consensus Criteria
I have a long-term infection after knee replacement and need surgery to place an antibiotic device.

Exclusion Criteria

I am unable to give consent by myself.
Allergies to study materials (cement, vancomycin, tobramycin)
I have an infection at my knee replacement site.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Surgery and Initial Treatment

Surgery to remove the artificial knee and place an antibiotic spacer or new artificial knee with antibiotic cement, followed by 6 weeks of IV antibiotics

6 weeks
1 visit (in-person) for surgery, followed by regular monitoring

Postoperative Monitoring

Participants are monitored for complications and recovery progress, with questionnaires administered at 6 weeks, 6 months, 12 months, and 24 months

24 months
Multiple visits (in-person and virtual) at specified intervals

Follow-up

Participants are monitored for long-term outcomes, including pain, function, and satisfaction

5 years

What Are the Treatments Tested in This Trial?

Interventions

  • All-cement articulating spacer
  • Real-component articulating spacer
Trial Overview The study compares two treatments for infected knee replacements: one-stage revision using a special cement that releases antibiotics, allowing near-normal activity but may need future replacement; versus two-stage revision which uses a temporary spacer then later surgery for durable joint placement.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: ObservationExperimental Treatment3 Interventions
Group II: All-cement articulating spacerActive Control1 Intervention
Group III: Durable, real-component articulating spacerActive Control1 Intervention

All-cement articulating spacer is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Antibiotic spacer for:
🇪🇺
Approved in European Union as Articulating antibiotic spacer for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials
1,674
Recruited
989,000+

Published Research Related to This Trial

Articulating antibiotic spacers used during two-stage exchange arthroplasty for infected total knee and hip replacements have an infection eradication rate of about 90%, making them highly effective.
These spacers also lead to better outcomes, including a higher range of motion after reimplantation and lower complication rates compared to nonarticulating spacers, indicating their safety and efficacy in appropriate patients.
Point/Counterpoint: Nonarticulating vs Articulating Spacers for Resection Arthroplasty of the Knee or Hip.Wyles, CC., Abdel, MP.[2021]
Articulating cement spacers can be safely maintained for up to 7 years in patients with severe knee conditions, providing pain relief and improved function without major complications or signs of recurrent infection during that time.
However, the case highlights the risk of progressive bone loss and the potential for mechanical issues, such as fractures, necessitating careful monitoring and consideration for future surgeries like total knee arthroplasty.
Antibiotic-impregnated articulating cement spacer maintained for 7 years in situ for two-stage primary total knee arthroplasty: a case report.Park, YB., Ha, CW., Jang, JW., et al.[2020]
A new method for creating intraoperatively-made cement-on-cement antibiotic-loaded articulating spacers for infected total knee arthroplasty was developed, allowing for customization in size and antibiotic delivery without increasing surgical time.
In a study of 17 patients treated between 2004 and 2007, this method showed potential benefits in improving knee mobility and function during the recovery period, although one patient required amputation due to persistent infection.
Intraoperatively-made cement-on-cement antibiotic-loaded articulating spacer for infected total knee arthroplasty.Shen, H., Zhang, X., Jiang, Y., et al.[2016]

Citations

All-Cement Spacers vs Sterilized Replanted Metal ...This study compared the outcomes of all-cement articulating spacers and sterilized replanted metal-polyethylene articulating spacers for PJI following TKA.
All-Cement vs Real-Component SpacersFew studies have compared different articulating spacer constructs. This study compares the outcomes of real-component and all-cement ...
Real-component Vs All-cement Articulating Spacers for ...The new artificial joint with antibiotic cement will function almost the same as the original artificial knee. This means that while the infection is healing ...
No difference in failure between static, articulating, and ...Comparing the Efficacy of Articulating Spacers in Two-Stage Revision for Periprosthetic Joint Infection Following Total Knee Arthroplasty ...
Success rates, characteristics, and costs of articulating ...Two-stage revision knee arthroplasty with antibiotic cement spacers has historically provided infection control rates above 80% [8], [13], [14], [15]. Although ...
Real-implant articulating spacers for chronic knee ...Real-implant articulating spacers for chronic knee prosthetic joint infection have similar infection control rates as all-cement spacer ...
Articulating spacers: what are available and how to utilize ...This study aimed to review the key concepts, types, and outcome evaluations of articulating spacers in the two-stage exchange for PJI.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security